French drug major Sanofi (SNYNF,SNY) Wednesday said it has entered into a definitive merger agreement to buy Kadmon Holdings, Inc. (KDMN), the developer of Rezurock, a recently FDA-approved treatment for chronic graft-versus-host disease.
In the deal, Kadmon shareholders will receive $9.50 per share in cash, which represents a total equity value of approximately $1.9 billion.
The offer price represents a premium of 79 percent over the closing price on September 7 and a premium of approximately 113 percent over the 60 trading days volume weighted average price.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.